Effects of mexidol on the antioxidative status of patients suffering from coronary heart disease with dislipidemia
Belaia, O.L.; Baĭder, L.M.; Kuropteva, Z.V.; Fomina, I.G.
Klinicheskaia Meditsina 83(10): 57-60
2005
ISSN/ISBN: 0023-2149 PMID: 16320849 Document Number: 8811
The subjects of the study were 36 patients suffering from coronary heart disease with exertional angina and postinfarction cardiosclerosis with dislipidemia. The patients were administered mexidol (2-ethyl-6-methyl-3-oxipyridin succinate), a domestically produced antioxidative agent, for 1 month in a dose of 325 mg/day together with conventional cardial therapy. The result was good and included clinical improvements and improvements in biochemical serum parameters: cholesterol level decreased by 10%, the level of low density lipoprotein cholesterol decreased by 25%, high density cholesterol level elevated by 15%. The intensity of lipid peroxidation lowered, which was manifested by decrease of the level of diene conjugates and TBA-reactive products by 27% and 42%, respectively. The patients' antioxidative status increased.
Document emailed within 1 workday
